Circulating resistin levels and risk of multiple myeloma in three prospective cohorts

Br J Cancer. 2017 Oct 10;117(8):1241-1245. doi: 10.1038/bjc.2017.282. Epub 2017 Aug 22.

Abstract

Background: Resistin is a polypeptide hormone secreted by adipose tissue. A prior hospital-based case-control study reported serum resistin levels to be inversely associated with risk of multiple myeloma (MM). To date, this association has not been investigated prospectively.

Methods: We measured resistin concentrations for pre-diagnosis peripheral blood samples from 178 MM cases and 358 individually matched controls from three cohorts participating in the MM cohort consortium.

Results: In overall analyses, higher resistin levels were weakly associated with reduced MM risk. For men, we observed a statistically significant inverse association between resistin levels and MM (odds ratio, 0.44; 95% confidence interval (CI) 0.24-0.83 and 0.54; 95% CI 0.29-0.99, for the third and fourth quartiles, respectively, vs the lowest quartile; Ptrend=0.03). No association was observed for women.

Conclusions: This study provides the first prospective evidence that low circulating resistin levels may be associated with an increased risk of MM, particularly for men.

MeSH terms

  • Adiponectin / blood
  • Aged
  • Australia / epidemiology
  • Case-Control Studies
  • Cohort Studies
  • Enzyme-Linked Immunosorbent Assay
  • Female
  • Humans
  • Incidence
  • Male
  • Middle Aged
  • Multiple Myeloma / blood
  • Multiple Myeloma / epidemiology*
  • Multivariate Analysis
  • Odds Ratio
  • Prospective Studies
  • Resistin / blood*
  • Risk
  • Sex Factors
  • United States / epidemiology

Substances

  • ADIPOQ protein, human
  • Adiponectin
  • RETN protein, human
  • Resistin